Prognostic markers for colorectal cancer: Expression of P53 and BCL2

World Journal of Surgery

Volumn 21, Issue 2, 1997, Pages 210-213

  Pereira, Hermínia ^a   Silva, Salete ^a   Julião, Rui ^a   Garcia, Palla ^a   Parpétua, Fátirna ^a  

^a HOSPITAL DE SANTA MARTA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INVASION; COLORECTAL CANCER; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOGENESIS; PROGNOSIS; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ADULT; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SAMPLE SIZE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031025033     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900218     Document Type: Article

References (33)

1. Levine, A.J., Momand, J., Finlay, C.A.: The P53 tumour suppressor gene. Nature 357:453, 1991
2. Thomas, G.: Advances in the genetics and molecular biology of colorectal tumors. Curr. Opin. Oncol. 6:406, 1994
3. Chen-Levy, Z., Noorse, J., Clearly, M.L.: The bcl2 candidate protooncogene product is a 24 kilodalton integral membrane protein expressed in lymphoid cell lines and lymphomas carrying the t (14:18) translocation. Mol. Cell. Biol. 9:701, 1989
4. Korsmeyer, S.Y.: bcl2 initiates a new category of oncogenes: regulators of cell death. Blood 80:879, 1989
5. Bosari, S., Momghini, L., Graziani, D., Lee, A.K.C., Murray, J.J., Gocci, G., Viale, G.: bcl2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas. Hum. Pathol. 26:534, 1995
6. Domagala, W., Harezga, B., Szadowska, A.: Nuclear P53 protein accumulates preferentially in medullary and high grade ductal but rarely in lobular carcinomas. Am. J. Pathol. 142:669, 1993
7. Newland, R.C., Dent, O.F., Lyttle, M.N.B., Chapuis, P.H., Bokey, L.E.: Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. Cancer 73:2076, 1994
8. Leek, R.D., Kaklamanis, I., Pezzela, F.: BLC2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer 69:135, 1994
9. Yandell, D., Thor, A.: P53 analysis in diagnostic pathology. Diagn. Mol. Pathol. 2:1, 1993
10. Midgley, C.A., Fisher, C.J., Bartek, J.: Analysis of P53 expression in human tumors: an antibody raised against P53 expressed in E. coll. J. Cell. Sci. 101:183, 1992
11. Soussi, T., Legtos, Y., Lubiu, R., Schlichtholz, B.: Multifactorial analysis of P53 alteration in human cancer: a review. Int. J. Cancer 57:1, 1994
12. Hall, P.A., Lane, D.P.: P53 in tumor pathology: can we trust immunohistochemistry? Revisited. J. Pathol. 772:1, 1994
13. Battifora, H.: Editorial: P53 immunohistochemistry: a word of caution. Hum. Pathol. 23:435, 1994
14. Baas, I.O., Mulder, Y.W.R., Offerhaus, J.A., Vogelstein, B., Hamilton, S.R.: An evaluation of six antibodies for immunohistochemistry of mutant P53 gene product in archival colorectal neoplasm. J. Pathol. 772:5, 1994
15. Wynford, T.D.: P53 in tumor pathology: can we trust immunocyto-chemestry? J. Pathol. 766:329, 1992
16. Bhargara, V., Thor, A., Deng, G., Ljung, B.M., Smith, H.: The association of P53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod. Pathol. 7:361, 1994
17. Batsakis, J., El-Naggar, A.: P53: fifteen years after discovery. Adv. Anat. Pathol. 2:71, 1995
18. Vogelstein, B., Fearon, R.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Lepeprt, M., Nacamura, V., White, R., Smits, A.M., Bos, J.L.: Genetic alterations during colorectal tumor development. N. Engl. J. Med. 319:525, 1988
19. Fearon, E.R., Vogelstein, B.: A genetic model for colorectal tumori-genesis. Cell 67:759, 1990
20. Bosari, S., Viali, G., Bossi, P.: Cytoplasmic accumulation of P53 protein: an independent prognostic indicator in colorectal adenocar-cinomas. J. Natl. Cancer Inst. 86:681, 1994
21. Dix, B.R., Robbins, P., Soong, R., Jenner, D., House, A.K., Icacopetta, B.J.: The common molecular genetic alterations in Dukes B and C colorectal carcinomas are not short term prognostic indicators of survival. Int. J. Cancer 59:747, 1994
22. Suzuli, H., Matsumoto, K., Koido, A., Iada, T., Fujino, I.: Correlation of P53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma. Surg. Today 24:85, 1994
23. Nathanson, S.D., Linden, M.D., Tender, P., Zarbo, R.Y., Jacobsen, G., Nelsen, L.T.: Relationship among P53 stage and prognosis of large bowel cancer. Dis. Colon Rectum 37:527, 1994
24. Hamelin, R., Laurent Puig, P., Olschway, S., Yego, N., Asselain, B., Renevikos, P., Girodet, Y., Salmon, R.J., Thomas, G.: Association of P53 mutations with short survival in colorectal cancer. Gastroenterology 706:42, 1994
25. Lambkin, H., Mothersill, C., Kelehan, P.: Variations in immunohistochemical detection of P53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J. Pathol. 772:13, 1994
26. Cattoretti, G., Pileri, S., Parravicini, C., Becker, M., Rilke, F.: Antigen unmasking on formalin-fixed paraffin-embedded tissue sections. J. Pathol. 777:83, 1993
27. Kerr, J.F.R., Winterford, C., Harmon, B.U.: Apoptosis. Cancer 73: 2013, 1994
28. Korsmeyer, S.Y.: bcl2 initiates a new category of oncogenes: regulators of cell death. Blood 80:879, 1993
29. Pezzela, F., Gatter, K.: What is the value of BCL2 protein detection for histopathologists. Histopathology 26:89, 1995
30. Harris, L.A.: Editorial: What does BCL2 means in solid tumours: friend or foe. Ann. Oncol. 5:388, 1994
31. Dogliani, C., Dei Tos, A.P., Laurino, L.: The prevalence of BCL2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 424:47, 1994
32. Sinicrope, F.A., Ruan, S.B., Cleary, K.R., Stephens, L.C., Lee, J.J., Levin, B.: BCL2 and P53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 55:237, 1995
33. Dowell, S., Hall, P.: The P53 tumor suppressor gene and tumor prognosis: is there a relationship. J. Pathol. 777:221, 1995